Reversing Immune Aging to Improve Immunotherapy Outcomes

Age-related immune decline may limit cancer immunotherapy effectiveness, particularly in patients ages 75 and older. Researchers are exploring mRNA-based immune rejuvenation and senolytics as potential solutions, with a growing number of human trials now testing whether targeting immune aging can improve treatment response. Translating these findings more broadly will require addressing safety concerns and the complexity of human immune aging.